A statement released earlier today by Joh. Berenberg Gossler & Co. KG about RHOEN-KLINIKUM (ETR:RHK) bumps the target price to 28.00EUR
- Updated: September 24, 2016
Joh. Berenberg Gossler & Co. KG bumped up the target of RHOEN-KLINIKUM (ETR:RHK) to 28.00EUR stating a potential upside of 0.03%.
On Wednesday September 21, 2016, Joh. Berenberg Gossler & Co. KG released a statement for RHOEN-KLINIKUM (ETR:RHK) bumped up the target price from 0.00EUR to 28.00EUR that suggested an upside of 0.03%.
Boasting a price of 27.26EUR, RHOEN-KLINIKUM (ETR:RHK) traded 0.00% even on the day. With the last stock price close up 0.00% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. RHOEN-KLINIKUM has recorded a 50-day average of 0.00EUR and a two hundred day average of 0.00EUR. Volume of trade held steady, with 0 shares of RHK changing hands on par with the typical 0
With a total market value of 0 EUR, RHOEN-KLINIKUM has with a one year low of 0.00EUR and a one year high of 0.00EUR .
Brief Synopsis About RHOEN-KLINIKUM (ETR:RHK)
Rhoen Klinikum AG is a Germany-based provider of health care services. It operates acute hospitals, medical care centers and rehabilitation hospitals across Germany: six clinics on Campus Bad Neustadt, including the Cardiovascular Clinic, the Frankenklinik for the Rehabilitation of Cardiovascular Patients, the Clinic for Hand Surgery, the Neurological Clinic, the Psychosomatic Clinic and the Saaletalklinik with two additional addiction therapy facilities; Klinikum Frankfurt (Oder) comprises clinics, psychiatric outpatient institutions and day clinics; University Hospital Giessen and Marburg (UKGM) offers medical services, modern diagnostics and comprehensive therapy in various areas, including ophthalmology, trauma surgery and dentistry, and Zentralklinik Bad Berka provides health care services to patients with thoracic, pulmonary and vascular diseases, tumors, neurological conditions, and diseases of the spinal column, joints and heart, among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.